Consequences of enterohaemorrhagic Escherichia coli infection for the vascular endothelium

Thrombosis and Haemostasis

Volumn 94, Issue 2, 2005, Pages 312-318

  Bielaszewska, Martina ^a   Karch, Helge ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Cytolethal distending toxin; Enterohaemorrhagic Escherichia coli; Haemolytic uraemic syndrome; Microvascular endothelial damage; Shiga toxin

Indexed keywords

CELL ADHESION MOLECULE; CHEMOKINE; CYTOKINE; HEMOLYSIN; SHIGA TOXIN;

APOPTOSIS; BACTERIAL INFECTION; BACTERIAL STRAIN; BACTERIAL VIRULENCE; CELL STIMULATION; CYTOKINE PRODUCTION; CYTOTOXICITY; ENDOTHELIUM CELL; ENDOTHELIUM LESION; ESCHERICHIA COLI; HEMOLYTIC UREMIC SYNDROME; HEMORRHAGIC COLITIS; HISTOPATHOLOGY; HOST CELL; MICROVASCULATURE; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN SYNTHESIS; REVIEW; THROMBOSIS; VASCULAR ENDOTHELIUM;

ANIMALS; APOPTOSIS; BACTERIAL TOXINS; CELLS, CULTURED; CYTOTOXINS; ENDOTHELIUM, VASCULAR; ESCHERICHIA COLI INFECTIONS; ESCHERICHIA COLI O157; HEMOLYSIN PROTEINS; HEMOLYTIC-UREMIC SYNDROME; HUMANS; INFLAMMATION; INTESTINES; MICROCIRCULATION; SHIGA TOXIN; SUBTILISINS; VIRULENCE FACTORS;

EID: 23744481459     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH05-04-0265     Document Type: Review

References (140)

1. Karmali MA. Infection by verocytotoxin-producing Escherichia coli. Clin Microbiol Rev 1989; 2: 1538.
2. Karmali MA. Infection by Shiga toxin-producing Escherichia coli: an over-view. Mol Biotechnol 2004; 26: 117-22.
3. Tarr PI, Gordon CA, Chandler WL. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet 2005; 365: 1073-86.
4. Banatvala N, Griffin PM et al. The United States national prospective hemolytic uremic syndrome study: microbiologic, serologic, clinical, and epidemiologic findings. J Infect Dis 2001; 183: 1063-70.
5. Karch H, Bielaszewska M et al. Epidemiology and diagnosis of Shigatoxin-producing Escherichia coli infections. Diagn Microbiol Infect Dis 1999; 34: 229-43.
6. Karmali MA, Steele BT, Petric M et al. Sporadic cases of haemolytic-uraemic syndrome associated with faecal cytotoxin and cytotoxin-producing Escherichia coli in stools. Lancet 1983; 1: 61920.
7. Karmali MA, Petric M, Lim C et al. The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli. J Infect Dis 1985; 151: 775-82.
8. Karch H, Bielaszewska M. Sorbitol-fermenting Shiga toxin-producing Escherichia coli O157: H-strains: epidemiology, phenotypic and molecular characteristics, and microbiological diagnosis. J Clin Microbiol 2001; 39: 2043-9.
9. Friedrich AW et al. Escherichia coli harboring Shiga toxin 2 gene variants: frequency and association with clinical symptoms. J Infect Dis 2002; 185: 74-84.
10. Gerber A, Karch H et al. Clinical course and the role of Shiga toxin-producing Escherichia coli infection in the hemolytic-uremic syndrome in pediatric patients, 1997-2000, in Germany and Austria: a prospective study. J Infect Dis 2002; 186: 493-500.
11. Tozzi AE, Caprioli A, Minelli F et al. Shiga toxin-producing Escherichia coli infections associated with hemolytic uremic syndrome, Italy, 1988-2000. Emerg Infect Dis 2003; 9: 106-8.
12. Elliott EJ, Robins-Browne RM, O'Loughlin EV et al. Nationwide study of haemolytic uraemic syndrome: clinical, microbiological, and epidemiological features. Arch Dis Child 2001; 85: 125-31.
13. Bell BP et al. A multistate outbreak of Escherichia coli O157: H7-associated bloody diarrhea and hemolytic uremic syndrome from hamburgers. The Washington experience. JAMA 1994; 272: 1349-53.
14. Wong CS, Jelacic S, Habeeb RL et al. The risk of the hemolytic uremic syndrome after antibiotic treatment of Escherichia coli O157: H7 infections. N Engl J Med 2000; 26: 1930-6.
15. Dundas S et al. The central Scotland Escherichia coli O157: H7 outbreak: risk factors for the hemolytic uremic syndrome and death among hospitalized patients. Clin Infect Dis 2001; 33: 923-31.
16. Andreoli SP et al. Hemolytic uremic syndrome: epidemiology, pathophysiology, and therapy. Pediatr Nephrol 2002; 17: 293-8.
17. Laschke MW et al. Intravital fluorescence microscopy: a novel tool for the study of the interaction of Staphylococcus aureus with the microvascular endothelium in vivo. J Infect Dis 2005; 191: 435-43.
18. Dehio C. Bartonella interactions with endothelial cells and erythrocytes. Trends Microbiol 2001; 9: 279-85.
19. Dehio C. Recent progress in understanding Bartonella-induced vascular proliferation. Curr Opin Microbiol 2003; 6: 61-5.
20. Raife T, Friedman KD, Fenwick B. Lepirudin prevents lethal effects of Shiga toxin in a canine model. Thromb Haemost 2004; 92: 387-93.
21. Richardson SE, Rotman TA, Jay V et al. Experimental verocytotoxemia in rabbits. Infect Immun 1992; 60: 4154-67.
22. Bielaszewska M, Clarke I, Karmali MA et al. Localization of intravenously administered verocytotoxins (Shiga-like toxins) 1 and 2 in rabbits immunized with homologous and heterologous toxoids and toxin subunits. Infect Immun 1997; 65: 2509-16.
23. Proulx F, Seidman EG, Karpman D. Pathogenesis of Shiga toxin-associated hemolytic uremic syndrome. Pediatr Res 2001; 50: 163-71.
24. Schmidt H, Scheef J, Huppertz HI et al. Escherichia coli O157: H7 and O157: H- strains that do not produce Shiga toxin: phenotypic and genetic characterization of isolates associated with diarrhea and hemolytic-uremic syndrome. J Clin Microbiol 1999; 37: 3491-6.
25. Taylor FB Jr, Tesh VL, DeBault L et al. Characterization of the baboon responses to Shiga-like toxin: descriptive study of a new primate model of toxic responses to Stx-1. Am J Pathol 1999; 154: 1285-99.
26. Bitzan M, te Loo DM. Interaction of Shiga toxin with endothelial cells. Methods Mol Med 2003; 73: 243-62.
27. Richardson SE, Karmali MA, Becker LE et al. The histopathology of the hemolytic uremic syndrome associated with verocytotoxin-producing Escherichia coli infections. Hum Pathol 1988; 19: 1102-8.
28. Inward CD, Howie AJ et al. Renal histopathology in fatal cases of diarrhoea-associated haemolytic uraemic syndrome. Pediatr Nephrol 1997; 11: 556-9.
29. Riella MC, George CR, Hickman RO et al. Renal microangiopathy of the hemolytic-uremic syndrome in childhood. Nephron 1976; 17: 188-203.
30. Habib R. Pathology of the hemolytic-uremic syndrome. In: Hemolytic uremic syndrome and thrombotic thrombocytopenic purpura Kaplan BS, Trompeter RS, Moake JL, eds). New York: Marcel Dekker, 1992; 315-53.
31. van Setten PA, Monnens LA et al. Effects of verocytotoxin-1 on nonadherent human monocytes: binding characteristics, protein synthesis, and induction of cytokine release. Blood 1996; 88: 174-83.
32. Harrison LM, van Haaften WCE, Tesh VL. Regulation of proinflammatory cytokine expression by Shiga toxin 1 and/or lipopolysaccharides in the human monocytic cell line THP-1. Infect Immun 2004; 72: 2618-27.
33. Harrison LM, Cherla RP et al. Comparative evaluation of apoptosis induced by Shiga toxin 1 and/or lipopolysaccharides in human monocytic and macrophage-like cells. Microb Pathog 2005; 38: 63-76.
34. Te Loo DM, Monnens LA, van Der Velden TJ et al. Binding and transfer of verocytotoxin by polymorphonuclear leukocytes in hemolytic uremic syndrome. Blood 2000; 95: 3396-402.
35. Te Loo DM, van Hinsbergh VW et al. Detection of verocytotoxin bound to circulating polymorphonuclear leukocytes of patients with hemolytic uremic syndrome. J Am Soc Nephrol 2001; 12: 800-6.
36. Liu J, Akahoshi T, Sasahana T et al. Inhibition of neutrophil apoptosis by verotoxin 2 derived from Escherichia coli O157: H7. Infect Immun 1999; 67: 6203-5.
37. Karpman D, Papadopoulou D, Nilsson K et al. Platelet activation by Shiga toxin and circulatory factors as a pathogenetic mechanism in the hemolytic uremic syndrome. Blood 2001; 97: 3100-8.
38. Hughes AK, Stricklett PK, Kohan DE. Shiga toxin 1 regulation of cytokine production by human proximal tubule cells. Kidney Int 1998; 54: 1093-106.
39. Upadhyaya K, Barwick K, Fishaut M et al. The importance of nonrenal involvement in hemolytic-uremic syndrome. Pediatrics 1980; 65: 115-20.
40. Tsai HM, Chandler WL, Sarode R et al. Von Willebrand factor and von Willebrand factor-cleaving metalloprotease activity in Escherichia coli O157: H7-associated hemolytic uremic syndrome. Pediatr Res 2001; 49: 653-9.
41. Griffin PM, Olmstead LC, Petras RE. Escherichia coli O157: H7-associated colitis. Gastroenterology 1990; 99: 142-9.
42. Chandler WL, Jelacic S, Boster DR et al. Prothrombotic coagulation abnormalities associated with Escherichia coli O157: H7 infections. N Engl J Med 2002; 346: 23-32.
43. Tarr PI. Basic fibroblast growth factor and Shiga toxin-O157: H7-associated hemolytic uremic syndrome. J Am Soc Nephrol 2002; 13: 817-20.
44. Nevard CH, Jurd KM, Lane DA et al. Activation of coagulation and fibrinolysis in childhood diarrhoea-associated haemolytic uraemic syndrome. Thromb Haemost 1997; 8: 1450-5.
45. van de Kar NC, van Hinsbergh VW, Brommer EJ et al. The fibrinolytic system in the hemolytic uremic syndrome: in vivo and in vitro studies. Pediatr Res 1994; 36: 257-64.
46. van Geet C, Proesmans W et al. Activation of both coagulation and fibrinolysis in childhood hemolytic uremic syndrome. Kidney Int 1998; 54: 1324-30.
47. Bergstein JM, Riley BS, Bang NU. Role of plasminogen-activator inhibitor type 1 in the pathogenesis and outcome of the hemolytic uremic syndrome. N Engl J Med 1992; 327: 755-9.
48. Proulx F, Turgeon JP, Litalien C et al. Inflammatory mediators in Escherichia coli O157: H7 hemorrhagic colitis and hemolytic-uremic syndrome. Pediatr Infect Dis J 1998; 17: 899-904.
49. Proulx F, Litalien C, Turgeon JP et al. Circulating levels of transforming growth factor-beta1 and lymphokines among children with hemolytic uremic syndrome. Am J Kidney Dis 2000; 35: 29-34.
50. Smith JM, Jones F, Ciol MA et al. Platelet-activating factor and Escherichia coli O157: H7 infections. Pediatr Nephrol 2002; 17: 1047-52.
51. Nevard CH, Blann AD et al. Markers of endothelial cell activation and injury in childhood haemolytic uraemic syndrome. Pediatr Nephrol 1999; 13: 487-92.
52. Forsyth KD, Simpson AC, Fitzpatrick MM et al. Neutrophil-mediated endothelial injury in haemolytic uraemic syndrome. Lancet 1989; 2: 411-4.
53. Hughes DA, Smith GC et al. The neutrophil oxidative burst in diarrhea-associated haemolytic uraemic syndrome. Pediatr Nephrol 1996; 10: 445-7.
54. Fitzpatrick MM, Shah V, Trompeter RS et al. Interleukin-8 and polymorphoneutrophil leucocyte activation in hemolytic uremic syndrome of childhood. Kidney Int 1992; 42: 951-6.
55. Bell BP, Griffin PM, Lozano P et al. Predictors of hemolytic uremic syndrome in children during a large outbreak of Escherichia coli O157: H7 infections. Pediatrics 1997; 100: E12.
56. Buteau C, Proulx F, Chaibou M et al. Leukocytosis in children with Escherichia coli O157: H7 enteritis developing the hemolytic uremic syndrome. Pediatr Infect Dis J 2000; 19: 642-7.
57. Pavia AT, Nichols CR, Green DP et al. Hemolytic-uremic syndrome during an outbreak of Escherichia coli O157: H7 infections in institutions for mentally retarded persons: clinical and epidemiologic observations. J Pediatr 1990; 116: 544-51.
58. Walters MD, Matthei IE, Kay R et al. The polymorphonuclear leukocyte count in childhood haemolytic uraemic syndrome. Pediatr Nephrol 1989; 3: 130-4.
59. Coad NA, Marshall T, Rowe B et al. Changes in the postenteropathic form of the hemolytic uremic syndrome in children. Clin Nephrol 1991; 35: 10-16.
60. Vierzig A, Roth B, Querfeld U et al. A 12-year-old boy with fatal hemolytic uremic syndrome, excessive neutrophilia and elevated endogenous granulocyte-colony-stimulating-factor serum concentrations. Clin Nephrol 1998; 50: 56-9.
61. van Setten PA, Hinsbergh MV, Van Den Heuvel LPWJ et al. Monocyte chemoattractant protein-1 and interleukin-8 in urine and serum of patients with hemolytic uremic syndrome. Pediatr Res 1998; 43: 759-67.
62. van de Kar NCAJ, Sauerwein RW, Demacker PNM et al. Plasma cytokine levels in hemolytic uremic syndrome. Nephron 1995; 71: 309-13.
63. Karpman D, Andreasson A, Thysell H et al. Cytokines in childhood hemolytic uremic syndrome and thrombotic thrombocytopenic purpura. Pediatr Nephrol 1995; 9: 694-9.
64. Yamamoto T, Isokawa S, Miyata H et al. Evaluation of thrombomodulin and tumor necrosis factor-alpha levels in patients with hemolytic uremic syndrome caused by enterohemorrhagic Escherichia coli O157: H7 infection. Nippon Jinzo Gakkai Shi 1999; 41: 60-4.
65. Inward CD, Varagunam M, Adu D et al. Cytokines in haemolytic uraemic syndrome associated with verocytotoxin-producing Escherichia coli infection. Arch Dis Child 1997; 77: 145-7.
66. O'Brien AD, Tesh VL et al. Shiga toxin: biochemistry, genetics, mode of action, and role in pathogenesis. Curr Top Microbiol Immunol 1992; 180: 65-94.
67. Sandvig K. Shiga toxins. Toxicon 2001; 39: 1629-35.
68. Jackson MP, Neil RJ, O'Brien AD et al. Nucleotide sequence analysis and comparison of the structural genes for Shiga-like toxin I and Shiga-like toxin II encoded by bacteriophages from Escherichia coli 933. FEMS Microbiol Lett 1987; 44: 109-14.
69. 1c) in Escherichia coli isolated from humans. J Clin Microbiol 2002; 40: 1441-6.
70. Friedrich AW, Borell J, Bielaszewska M et al. Shiga toxin 1c-producing Escherichia coli strains: Phenotypic and genetic characterization and association with human disease. J Clin Microbiol 2003; 41: 2448-53.
71. Kuczius T, Bielaszewska M, Friedrich AW et al. A rapid method for the discrimination of genes encoding classical Shiga toxin (Stx) 1 and its variants, Stx1c and Stx1d, in Escherichia coli. Mol Nutr Food Res 2004; 48: 515-21.
72. Schmitt CK, McKee ML, O'Brien AD. Two copies of Shiga-like toxin II-related genes common in enterohemorrhagic Escherichia coli strains are responsible for the antigenic heterogeneity of the O157: H- strain E32511. Infect Immun 1991; 59: 1065-73.
73. Pierard D, Muyldermas G, Moriau L et al. Identification of new Verocytotoxin type 2 variant B-subunit genes in human and animal Escherichia coli isolates. J Clin Microbiol 1998; 36: 3317-22.
74. Melton-Celsa AR, Darnell SC, O'Brien AD. Activation of Shiga-like toxins by mouse and human intestinal mucus correlates with virulence of enterohemorrhagic Escherichia coli O91: H21 isolates in orally infected, streptomycin-treated mice. Infect Immun 1996; 64: 1569-76.
75. Weinstein DL, Jackson MP, Samuel JE et al. Cloning and sequencing of a Shiga-like toxin type II variant from an Escherichia coli strain responsible for edema disease of swine. J Bacteriol 1988; 170: 4223-30.
76. Ostroff SM, Tarr PI, Neill MA et al. Toxin genotypes and plasmid profiles as determinants of systemic sequelae in Escherichia coli O157: H7 infections. J Infect Dis 1989; 160: 994-8.
77. Boerlin P, McEwen SA, Boerlin-Petzold F et al. Association between virulence factors of Shiga toxin-producing Escherichia coli and disease in humans. J Clin Microbiol 1999; 37: 497-503.
78. Zhang W, Bielaszewska M, Friedrich AW et al. Transcriptional analysis of genes encoding Shiga toxin 2 and its variants in Escherichia coli. Appl Environ Microbiol 2005; 71: 558-61.
79. Hurley BP, Thorpe CM, Acheson DW. Shiga toxin translocation across intestinal epithelial cells is enhanced by neutrophil transmigration. Infect Immun 2001; 69: 6148-55.
80. Tazzari PL, Ricci F, Carnicelli D et al. Flow cytometry detection of Shiga toxins in the blood from children with hemolytic uremic syndrome. Cytometry B Clin Cytom 2004; 61: 40-4.
81. Lingwood CA. Shiga toxin receptor glycolipid binding. Pathology and utility. Methods Mol Med 2003; 73: 165-86.
82. Boyd B, Lingwood C. Verotoxin receptor glycolipid in human renal tissue. Nephron 1989; 51: 207-10.
83. Jacewicz MS, Acheson DW, Binion DG et al. Responses of human intestinal microvascular endothelial cells to Shiga toxins 1 and 2 and pathogenesis of hemorrhagic colitis. Infect Immun 1999; 67: 1439-44.
84. Ren J, Utsunomiya I, Tagushi K et al. Localization of verotoxin receptors in nervous system. Brain Res 1999; 825: 183-8.
85. Sandvig K, Olsnes S, Brown JE et al. Endocytosis from coated pits of Shiga toxin: a glycolipid-binding protein from Shigella dysenteriae 1. J Cell Biol 1989; 108: 1331-43.
86. Endo Y, Tsurugi K, Yutsudo T et al. Site of action of a Vero toxin (VT2) from Escherichia coli O157: H7 and of Shiga toxin on eukaryotic ribosomes. RNA N-glycosidase activity of the toxins. Eur J Biochem 1988; 17145-50.
87. Saxena SK, O'Brien AD, Ackerman EJ. Shiga toxin, Shiga-like toxin II variant, and ricin are all single-site RNA N-glycosidases of 28 S RNA when microinjected into Xenopus oocytes. J Biol Chem 1989; 264: 596-601.
88. Yoshida T, Fukada M, Koide N et al. Primary cultures of human endothelial cells are susceptible to low doses of Shiga toxins and undergo apoptosis. J Infect Dis 1999; 180: 2048-52.
89. Ergonul Z, Hughes AK, Kohan DE. Induction of apoptosis of human brain microvascular endothelial cells by Shiga toxin 1. J Infect Dis 2003; 187: 154-8.
90. Bombeli T, Schwartz BR, Harlan JM. Endothelial cells undergoing apoptosis become proadhesive for nonactivated platelets. Blood 1999; 93: 3831-8.
91. Cherla RP, Lee SY, Tesh VL. Shigatoxins and apoptosis. FEMS Microbiol Lett 2003; 228: 159-66.
92. Pijpers AH, van Setten PA, van den Heuvel LP et al. Verocytotoxin-induced apoptosis of human microvascular endothelial cells. J Am Soc Nephrol 2001; 12: 767-78.
93. Brigotti M, Alfieri R, Sestili P et al. Damage to nuclear DNA induced by Shiga toxin 1 and ricin in human endothelial cells. FASEB J 2002; 16: 365-72.
94. Obrig TG, Louise CB, Lingwood CA et al. Endothelial heterogeneity in Shiga toxin receptors and responses. J Biol Chem 1993; 268: 15484-8.
95. O'Loughlin EV, Robins-Browne RM. Effect of Shiga toxin and Shiga-like toxins on eukaryotic cells. Microbes Infect 2001; 3: 493-507.
96. Obrig TG, Del Vecchio PJ, Brown JE et al. Direct cytotoxic action of Shiga toxin on human vascular endothelial cells. Infect Immun 1988; 56: 2373-8.
97. van Setten PA, van Hinsberg VW, van-der Velden TJ et al. Effects of TNF alpha on verocytotoxin cytotoxicity in purified human glomerular microvascular endothelial cells. Kidney Int 1997; 51: 1245-56.
98. Louise B, Obrig TG. Specific interaction of Escherichia coli O157: H7-derived Shiga-like toxin II with human renal endothelial cells. J Infect Dis 1995; 172: 1397-401.
99. Hutchinson JS, Stanimirovic D, Shapiro A et al. Shiga toxin (verotoxin) toxicity in human cerebral endothelial cells. In: Escherichia coli O157: H7 and other Shiga toxin-producing Escherichia coli (Kaper JB, O'Brien AD eds). American Society for Microbiology, Washington DC, 1998; 323-8.
100. Ramegowda B, Samuel JE, Tesh VL. Interaction of Shiga toxins with human brain microvascular endothelial cells: cytokines as sensitizing agents. J Infect Dis 1999; 180: 1205-13.
101. Keusch GT, Acheson DW, Aaldering L et al. Comparison of the effects of Shiga-like toxin 1 on cytokine-and butyrate-treated human umbilical and saphenous vein endothelial cells. J Infect Dis 1996; 173: 1164-70.
102. Simon M, Cleary TG, Hernandez JD et al. Shiga toxin 1 elicits diverse biologic responses in mesangial cells. Kidney Int 1998; 54: 1117-27.
103. Matussek A, Lauber J, Bergau A et al. Molecular and functional analysis of Shiga toxin-induced response patterns in human vascular endothelial cells. Blood 2003; 102: 1323-32.
104. Eisenhauer PB, Jacewicz MS, Conn KJ et al. Escherichia coli Shiga toxin 1 and TNF-alpha induce cytokine release by human cerebral microvascular endothelial cells. Microb Pathog 2004; 36: 189-96.
105. Thorpe CM, Hurley BF, Lincicome LL et al. Shiga toxins stimulate secretion of interleukin-8 from intestinal epithelial cells. Infect Immun 1999; 67: 5985-93.
106. Thorpe CM, Smith WE, Hurley BP et al. Shiga toxins induce, superinduce, and stabilize a variety of C-X-C chemokine mRNAs in intestinal epithelial cells, resulting in increased chemokine expression. Infect Immun 2001; 69: 6140-47.
107. van de Kar NC, Monnens LA, Karmali MA et al. Tumor necrosis factor and interleukin-1 induce expression of the verocytotoxin receptor globotriaosyl-ceramide on human endothelial cells: implications for the pathogenesis of the hemolytic uremic syndrome. Blood 1992; 80: 2755-64.
108. Kaye SA, Louise CB, Boyd B et al. Shiga toxin-associated hemolytic uremic syndrome: interleukin-1 enhancement of Shiga toxin cytotoxicity toward human vascular endothelial cells in vitro. Infect Immun 1993; 61: 3886-91.
109. Louise, CB, Obrig TG. Shiga toxin-associated hemolytic uremic syndrome: combined cytotoxic effects of Shiga toxin and lipopolysaccharide (endotoxin) on human vascular endothelial cells in vitro. Infect Immun 1992; 60: 1536-43.
110. Obrig TG, Seaner RM, Bentz M et al. Induction by sphingomyelinase of Shiga toxin receptor and Shiga toxin 2 sensitivity in human microvascular endothelial cells. Infect Immun. 2003; 71: 845-49.
111. Morigi M, Micheletti G, Figliuzzi M et al. Verotoxin-1 promotes leukocyte adhesion to cultured endothelial cells under physiologic flow conditions. Blood 1995; 86: 4553-58.
112. Morigi M, Galbusera M, Binda E et al. Verotoxin-1-induced up-regulation of adhesive molecules renders microvascular endothelial cells thrombogenic at high shear stress. Blood 2001; 98: 1828-35.
113. Zoja C, Angioletti S et al. Shiga toxin-2 triggers endothelial leukocyte adhesion and transmigration via NF-kappaB dependent up-regulation of IL-8 and MCP-1. Kidney Int 2002; 62: 846-56.
114. Bitzan MM, Wang Y, Lin J et al. Verotoxin and ricin have novel effects on preproendothelin-1 expression but fail to modify nitric oxide synthase (ecNOS) expression and NO production in vascular endothelium. J Clin Invest 1998; 101: 372-82.
115. Ishii H, Takada K, Higuchi T et al. Verotoxin-1 induces tissue factor expression in human umbilical vein endothelial cells through activation of NF-kappaB/Rel and AP-1. Thromb Haemost 2000; 84: 712-21.
116. Janka A, Bielaszewska M, Dobrindt U et al. Cytolethal distending toxin gene cluster in enterohemorrhagic Escherichia coli O157: H- and O157: H7: characterization and evolutionary considerations. Infect Immun 2003; 71, 3634-8.
117. Schmidt H, Beutin L, Karch H. Molecular analysis of the plasmid-encoded hemolysin of Escherichia coli O157: H7 strain EDL 933. Infect Immun 1995; 63: 1055-61.
118. 5 cytotoxins produced by Shiga toxigenic Escherichia coli. J Exp Med 2004; 200: 35-46.
119. Bielaszewska M et al. Characterization of cytolethal distending toxin genes and expression in Shiga toxin-producing Escherichia coli strains of non-O157 serogroups. Infect Immun 2004; 72: 1812-16.
120. Thelestam M, Frisan T. Cytolethal distending toxins. Rev Physiol Biochem Pharmacol 2004; 152: 111-133.
121. Cortes-Bratti X, Frisan T, Thelestam M. The cytolethal distending toxins induce DNA damage and cell cycle arrest. Toxicon 2001; 39: 1729-36.
122. Lara-Tejero M, Galan JE. CdtA, CdtB, and CdtC form a tripartite complex that is required for cytolethal distending toxin activity. Infect Immun 2001; 69: 4358-65.
123. Lara-Tejero M, Galan JE. A bacterial toxin that controls cell cycle progression as a deoxyribonuclease I-like protein. Science 2000; 290: 354-57.
124. Oswald E, Nougayrede JP, Taieb F et al. Bacterial toxins that modulate host cell-cycle progression. Curr Opin Microbiol 2005; 8: 83-91.
125. Elwell CA, Dreyfus LA. DNase I homologous residues in CdtB are critical for cytolethal distending toxin-mediated cell cycle arrest. Mol Microbiol 2000; 37: 952-63.
126. Deng K, Hansen EJ. A CdtA-CdtC complex can block killing of HeLa cells by Haemophilus ducreyi cytolethal distending toxin. Infect Immun 2003; 71: 6633-40.
127. Paton AW, Woodrow MC, Doyle RM et al. Molecular characterization of a Shiga-toxigenic Escherichia coli O113: H21 strain lacking eae responsible for a cluster of cases of hemolytic-uremic syndrome. J Clin Microbiol 1999; 37: 3357-61.
128. Bielaszewska M, Sinha B, Kuczius T et al. Cytolethal distending toxin from Shiga toxin-producing Escherichia coli O157 causes irreversible G2/M arrest, inhibition of proliferation and death of human endothelial cells. Infect Immun 2005; 73: 552-62.
129. Dobrindt U, Agerer F, Michaelis K et al. Analysis of genome plasticity in pathogenic and commensal Escherichia coli isolates by use of DNA arrays. J Bacteriol 2003; 185: 1831-40.
130. Mellmann A, Bielaszewska M, Zimmerhackl BL et al. Enterohemorrhagic Escherichia coli in human infection: in vivo evolution of a bacterial pathogen. Clin Infect Dis 2005; in press.
131. Bielaszewska M, Zhang W, Tarr PI et al. Molecular profiling and phenotype analysis of Escherichia coli O26: H11 and O26: NM: Secular and geographic consistency of enterohemorrhagic and enteropathogenic isolates. J Clin Microbiol 2005; in press.
132. Sonntag A, Prager R, Bielaszewska M et al. Phenotypic and genotypic analyses of enterohemorrhagic Escherichia coli O145 strains from patients in Germany. J Clin Microbiol 2004; 42: 95462.
133. Schmidt H, Maier E, Karch H et al. Pore-forming properties of the plasmid-encoded hemolysin of enterohemorrhagic Escherichia coli O157: H7. Eur J Biochem 1996; 241: 594-601.
134. Taneike I, Zhang HM, Wakisaka-Saito N et al. Enterohemolysin operon of Shiga toxin-producing Escherichia coli: a virulence function of inflammatory cytokine production from human monocytes. FEBS Lett 2002; 524: 219-24.
135. Brunder W, Schmidt H, Karch H. EspP, a novel extracellular serine protease of enterohaemorrhagic Escherichia coli O157: H7 cleaves human coagulation factor V. Mol Microbiol 1997; 24: 767-78.
136. Berin MC, Darfeuille-Michaud A, Egan LJ et al. Role of EHEC O157: H7 virulence factors in the activation of intestinal epithelial cell NF-kappaB and MAP kinase pathways and the upregulated expression of interleukin 8. Cell Microbiol 2002; 4: 635-48.
137. Rogers TJ, Paton AW, McColl SR et al. Enhanced CXC chemokine responses of human colonic epithelial cells to locus of enterocyte effacement-negative Shiga-toxigenic Escherichia coli. Infect Immun 2003; 71: 5623-32.
138. Karmali MA. Prospects for preventing serious systemic toxemic complications of Shiga toxin-producing Escherichia coli infections using Shiga toxin receptor analogues. J Infect Dis 2004; 189: 355-9.
139. MacConnachie AA, Todd WT. Potential therapeutic agents for the prevention and treatment of haemolytic uraemic syndrome in Shiga toxin producing Escherichia coli infection. Curr Opin Infect Dis 2004; 17: 479-82.
140. Uchida T. STX-liposome conjugates as candidate vaccines. Drugs Today 2003; 39: 673-93.